ANNX vs ANTX

Annexon, Inc. vs AN2 Therapeutics, Inc. — Valuation Comparison 2026

ANNX

Biotechnology
Annexon, Inc.
Quality
4.2
out of 10
Value Trap
36
LOW
Price
$5.37
Last close
Models
7/13
Active
VS

ANTX

Biotechnology
AN2 Therapeutics, Inc.
Quality
4.3
out of 10
Value Trap
18
SAFE
Price
$4.46
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ANNX Fair ValueANNX Upside ANTX Fair ValueANTX Upside
Bayesian DCF Intrinsic $1.97 -63.4% $2.01 -55.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.09 -98.4% $0.38 -91.4%
Dynamic NAV Asset-Based $2.02 -62.4% $2.77 -38.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ANNX vs ANTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ANNX vs ANTX — Which Stock Is More Undervalued?

ANTX scores higher with a 4.3/10 quality rating vs ANNX's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Annexon, Inc. (ANNX) and AN2 Therapeutics, Inc. (ANTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ANNX currently trades at $5.37 with a QOC of 4.2/10, while ANTX trades at $4.46 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).